TFF Pharmaceuticals Provides Update From Phase 2 Trial Of Tacrolimus Inhalation Powder; 13 Patients Now Enrolled; TFF TAC At ~20% Of The Oral Tacrolimus Dose Prevented Acute Rejection And Achieved >80% Of The Previous Oral Trough Blood Levels
Portfolio Pulse from Benzinga Newsdesk
TFF Pharmaceuticals has provided an update on its Phase 2 trial of Tacrolimus Inhalation Powder. The trial has enrolled 13 patients, and the inhalation powder at approximately 20% of the oral dose has prevented acute rejection and achieved over 80% of the previous oral trough blood levels.
August 06, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TFF Pharmaceuticals' Phase 2 trial of Tacrolimus Inhalation Powder shows promising results with 13 patients enrolled. The inhalation powder at 20% of the oral dose prevents acute rejection and achieves over 80% of the previous oral trough blood levels.
The positive update from the Phase 2 trial indicates that the Tacrolimus Inhalation Powder is effective at a lower dose, which could lead to better patient compliance and fewer side effects. This is likely to boost investor confidence and positively impact TFFP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100